Risk stratification and medical therapy of pulmonary arterial hypertension

Nazzareno Galiè, Richard N. Channick, Robert P. Frantz, Ekkehard Grünig, Zhi Cheng Jing, Olga Moiseeva, Ioana R. Preston, Tomas Pulido, Zeenat Safdar, Yuichi Tamura, Vallerie V. McLaughlin

Source: Eur Respir J, 53 (1) 1801889; 10.1183/13993003.01889-2018
Journal Issue: January
Disease area: Pulmonary vascular diseases

Congress or journal article abstractFull text journal articlePDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Nazzareno Galiè, Richard N. Channick, Robert P. Frantz, Ekkehard Grünig, Zhi Cheng Jing, Olga Moiseeva, Ioana R. Preston, Tomas Pulido, Zeenat Safdar, Yuichi Tamura, Vallerie V. McLaughlin. Risk stratification and medical therapy of pulmonary arterial hypertension. Eur Respir J, 53 (1) 1801889; 10.1183/13993003.01889-2018

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Risk assessment in pulmonary arterial hypertension
Source: Eur Respir J, 51 (3) 1702606; 10.1183/13993003.02606-2017
Year: 2018



Risk assessment in pulmonary arterial hypertension
Source: Eur Respir Rev 2016; 25: 390-398
Year: 2016



Risk assessment in pulmonary arterial hypertension
Source: Eur Respir J, 51 (3) 1800279; 10.1183/13993003.00279-2018
Year: 2018



Risk assessment, therapy and cardiovascular comorbidity in patients with pulmonary arterial hypertension
Source: Virtual Congress 2020 – Clinical evaluation, biomarkers and risk assessment of pulmonary hypertension
Year: 2020


Risk assessment in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
Source: Eur Respir J, 53 (6) 1802004; 10.1183/13993003.02004-2018
Year: 2019



Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension
Source: Eur Respir J, 50 (2) 1700889; 10.1183/13993003.00889-2017
Year: 2017



Risk stratification in pulmonary arterial hypertension (PAH)
Source: International Congress 2018 – New trends in the management of pulmonary hypertension
Year: 2018


Current medical treatment of pulmonary arterial hypertension
Source: School Course 2012 - Pulmonary hypertension and pulmonary vascular disease
Year: 2012



Current medical treatment of pulmonary arterial hypertension
Source: School Course 2014 - Pulmonary Hypertension and Pulmonary Vascular Disease
Year: 2014



Current medical treatment of pulmonary arterial hypertension
Source: ERS Skills course - Pulmonary hypertension and pulmonary vascular disease
Year: 2018

Current medical treatment of pulmonary arterial hypertension
Source: ERS Course 2017 - Pulmonary Hypertension and Pulmonary Vascular Disease
Year: 2017

Novel biomarkers for risk stratification in pulmonary arterial hypertension
Source: ERJ Open Res 2015; 1: 00008-2015
Year: 2015



Risk stratification and prognostic factors in patients with pulmonary arterial hypertension and comorbidities
Source: Virtual Congress 2020 – Clinical evaluation, biomarkers and risk assessment of pulmonary hypertension
Year: 2020


Analysis of mortality risk factors in a population with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
Source: Annual Congress 2010 - Pulmonary hypertension
Year: 2010


Pulmonary arterial hypertension: tailoring treatment to risk in the current era
Source: Eur Respir Rev, 26 (146) 170095; 10.1183/16000617.0095-2017
Year: 2017



Real-life data on the medical therapy of pulmonary arterial and chronic thromboembolic pulmonary hypertension
Source: International Congress 2017 – PAH and CTEPH
Year: 2017

Impact of age and comorbidity on risk stratification in idiopathic pulmonary arterial hypertension
Source: Eur Respir J, 51 (5) 1702310; 10.1183/13993003.02310-2017
Year: 2018



Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model
Source: Eur Respir J, 50 (2) 1700740; 10.1183/13993003.00740-2017
Year: 2017



Adherence to disease-specific drug treatment among patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension
Source: ERJ Open Res, 6 (4) 00299-2020; 10.1183/23120541.00299-2020
Year: 2020